Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug

LLY $918.00 52-Week Range $434.34 $928.60 P/E Ratio 135.20 By all accounts, Eli Lilly's Tirzepatide, the active ingredient in Mounjaro and Zepbound, is superior on paper to Semaglutide, the active ingredient in Ozempic and Wegovy, because it targets two hormones compared to one. However, currently in Phase 2 clinical trials, its secret weapon for weight loss targets three hormones as the ultimate triple threat. Eli Lilly operates in the medical sector, facing competition from upcoming GLP-1 contenders from ...